MEDICAID DUR PROGRAMS COULD REQUIRE "REMEDIAL" ACTIONS FROM PROVIDERS AS "MID-RANGE" RESPONSE; PRIVACY, SOFTWARE DESIGN ARE CHALLENGES -- HHS IG REPORT
State Medicaid drug utilization review programs should consider using "mid-range" interventions in response to provider practices that require more than an informational letter and less than punitive action, the HHS Inspector General suggests in a May report on the current status of state DUR programs.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth